Skip to main content

02 · Clinical Findings

GLP-1s confer better glycemic, CV outcomes than metformin

Healio Endocrinology1 min read

A three year observational study of adults with prediabetes and obesity found lower rates of progression to type 2 diabetes and all cause mortality, though prospective trials are still needed.

Image from the article by Healio Endocrinology: GLP-1s confer better glycemic, CV outcomes than metformin
Image: Healio Endocrinology

In a three-year observational study of matched adults with prediabetes and obesity, GLP-1 receptor agonists outperformed standard metformin therapy.

Patients taking GLP-1 drugs returned to normal blood sugar more often (37.3% vs. 29.3%) and progressed to type 2 diabetes less frequently (25.1% vs. 37%). They also experienced lower rates of all-cause mortality and cardiovascular events like stroke and heart failure.

Because the TriNetX analysis relies on medical records, researchers stress the findings are preliminary and require prospective trials.

DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾

This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.

Related context

How this story connects across the peptide landscape.

Continue reading · Clinical FindingsPeptide News / Clinical FindingsGLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKDPharmacy Times · Oct 27, 2026 · scroll to read